20 reports

  • Target
  • Official Title

Appetite (Eating) Disorders Global Clinical Trials Review, H##, 2018 HEA LTH CA REHEA LTH CA RE REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: NOV 2018 LIST OF TABLES LIST OF FIGURES Appetite (Eating) Disorders Global Clinical Trials Review, H##, 2018 outlines clin

  • Clinical Trial
  • Eating Disorder
  • World
  • Product Initiative
  • Shire plc
  • ADDITIONAL RESOURCES
  • disorders, such as beneficiaries only

According to ANAD data, only one in ## individuals with eating disorders actually receives treatment.

  • Clinic
  • Eating Disorder
  • Mental Health
  • United States
  • Forecast

There are only three industry-sponsored drugs in active clinical development for eating disorders, with two drugs in Phase II and one in Phase III.

  • Eating Disorder
  • Mental Health
  • Pathology
  • World
  • Demand

& nbsp; There are only three drugs in active clinical development for eating disorders, with two drugs in Phase II, and one in Phase III.

  • Eating Disorder
  • Mental Health
  • Pathology
  • World
  • Target
  • Clinical Trial profile. 33 Trial Title

CLINICAL TRIALS BY PHASE IN G## COUNTRIES BINGE EATING DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* BINGE EATING DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* BINGE EATING DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY

  • Clinical Trial
  • Eating Disorder
  • Neurology
  • Pharmaceutical
  • Shire plc
  • Featured News & Press Releases
  • lisdexamfetamine dimesylate - Drug Profile

Binge eating disorder is the most common eating disorder in adults. ## In addition to being more common than anorexia and bulimia combined, binge eating disorder is the most prevalent eating disorder among adult men. ## VYVANSE is

  • Eating Disorder
  • Mental Health
  • Therapy
  • United States
  • Product Initiative
  • Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants
  • Mar 20, 2017: Opiant Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa

" We recently completed the last patient last visit in our ongoing Phase ## trial of OPNT## for the treatment of Bulimia Nervosa, an eating disorder characterized by binging and purging that impacts more than ## million Americans annually.

  • Eating Disorder
  • Pharmaceutical
  • United States
  • Company
  • Opiant Pharmaceuticals, Inc.
  • Clinical Trial profile. 3 Trial Title
  • Clinical Trial Profile Snapshots

Reddy' s Under Fasting Condition GDCT## NCT##, ##/ ## Central Nervous System Binge Eating Disorder, Bulimia Nervosa, Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorders Completed Phase I Interventional fluoxetine hydrochlo

  • Clinical Trial
  • Drug Development
  • Eating Disorder
  • Therapy
  • Opiant Pharmaceuticals, Inc.
  • Clinical Trial profile. 47 Trial Title
  • Clinical Trial profile. 111 Trial Title

GDCT ID is the unique ID of GlobalData' s Pharma Intelligence Center clinical trial database Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collabora

  • Clinical Trial
  • Drug Development
  • Eating Disorder
  • Neurology
  • Insys Therapeutics, Inc.
  • outlines the main three types of psychotherapy used in BED treatment.
  • 4.1 ETIOLOGY AND PATHOPHYSIOLOGY

BED can develop from any eating disorder or progress into a different eating disorder.

  • Eating Disorder
  • Mental Health
  • Therapy
  • United States
  • Forecast

The report focuses on drugs and therapies being evaluated for Binge Eating Disorder treatment in active clinical development phases including phase ##, phase ##, phase ## and phase ## clinical trials.

  • Clinical Trial
  • Drug Development
  • Eating Disorder
  • Mental Health
  • Pathology

Insights into Binge Eating Disorder Pipeline ##.

  • Eating Disorder
  • Mental Health
  • World
  • Target
  • Clinical Trial Profile Snapshots

Clinical Trials by Phase in G## Countries BINGE EATING DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* BINGE EATING DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* BINGE EATING DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY

  • Clinical Trial
  • Eating Disorder
  • Neurology
  • Pharmaceutical
  • Shire plc
  • Omeros Corp
  • Binge Eating Disorder - Pipeline by Opiant Pharmaceuticals Inc, H2 2018

Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain.

  • Eating Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

2019 Binge Eating Disorder Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 ##.

  • Clinical Trial
  • Drug Development
  • Eating Disorder
  • Mental Health
  • Pathology

2019 Binge Eating Disorder Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets ##.

  • Clinical Trial
  • Drug Development
  • Eating Disorder
  • Mental Health
  • APAC
  • 4.1 BIBLIOGRAPHY
  • 3.1 DISEASE BACKGROUND

A study where ## consecutive adult patients were administered the Eating Disorder Examination (EDE), a semistructured investigator-based interview that assesses the associated psychological features of eating disorders, found that approximately ##% of patients wi

  • Eating Disorder
  • Mental Health
  • United States
  • World
  • Forecast

2019 Future of Binge Eating Disorder R& D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments ##.

  • Eating Disorder
  • Mental Health
  • Pharmaceutical
  • Therapy
  • Official Title
  • LATEST CLINICAL TRIALS NEWS ON BULIMIA NERVOSA

" Bulimia Nervosa is a serious and potentially life-threatening eating disorder for which new treatment options are desperately needed, " said Janet Treasure OBE, PhD, FRCP, FRCPsych, Professor of Psychiatry at King' s College London, and principal investigator of the s

  • Clinical Trial
  • Drug Development
  • Eating Disorder
  • Therapy
  • Opiant Pharmaceuticals, Inc.
  • Clinical Trial Profile Snapshots

## ## ## ## Japan ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## Italy Source: GlobalData' s Pharma Intelligence Center Clinical

  • Eating Disorder
  • Hospital
  • Neurology
  • World
  • Product Initiative